After H.C. Wainwright and Brookline Capital Markets gave Veru (NASDAQ: VERU) a Buy rating last month, the company received another Buy, this time from Oppenheimer. Analyst Leland Gershell assigned a Buy rating to Veru today and set a price target of $24.00. The company’s shares closed last Monday at $8.97.
According to TipRanks.com, Gershell is a 4-star analyst with an average return of 7.5% and a 40.6% success rate. Gershell covers the Healthcare sector, focusing on stocks such as Milestone Pharmaceuticals, BioMarin Pharmaceutical, and Corbus Pharmaceuticals.
Veru has an analyst consensus of Strong Buy, with a price target consensus of $21.33.
See today’s analyst top recommended stocks >>
Based on Veru’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $13.34 million and GAAP net loss of $2.85 million. In comparison, last year the company earned revenue of $9.94 million and had a GAAP net loss of $810.5K.
Based on the recent corporate insider activity of 6 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of VERU in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Veru, Inc. is an oncology and urology biopharmaceutical company. It develops medicines for prostate cancer treatment and prostate cancer supportive care as well as urology specialty pharmaceuticals. Its oncology drug candidates includes VERU-111, an oral alpha and beta tubulin inhibitor, which is in a phase 1b/2 study for the treatment of metastatic castration resistant prostate cancer; Zuclomiphene citrate, which is in a phase 2 clinical trial for the treatment of hot flashes in men undergoing prostate cancer hormonal therapies; and VERU-100, a long-acting GnRH antagonist 3 month subcutaneous depot, planned phase 2 clinical trial for the treatment of hormone sensitive advanced prostate cancer. The company’s urology specialty pharmaceutical drug candidate is TADFIN, a tadalafil and finasteride combination oral capsule, for the treatment of men with benign prostatic hyperplasia. Its commercial products include the FC2 Female/Internal condom for prevention of pregnancy and sexually transmitted infections and PREBOOST 4% benzocaine wipes for the prevention of premature ejaculation marketed as Roman Swipes by getroman.com. The company was founded by William R. Gargiulo Jr. and O.B. Parrish in 1996 and is headquartered in Miami, FL.
